President Obama’s year-old, $200 million Precision Medicine initiative (PMI) seems to be doing exactly what was intended, writes Heather Gartman.
Heather Gartman
Advertisement
Heather Gartman is Regional Managing Director (DC), inVentiv Health
Articles by Heather Gartman
Advertisement
Latest Updated Articles
- What “Precision Medicine” Means for Rare Diseases
March 3rd 2016
Advertisement
Advertisement
Trending on PharmExec
1
FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
2
The Rise of Direct-to-Patient Models in Pharma: Opportunities and Risks in Bypassing Traditional Distribution Channels
3
Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics
4
Ibrance Wins FDA Approval for HR-Positive, HER2-Positive Metastatic Breast Cancer Maintenance Therapy
5